Item
8.01. Other Events.
On
December 12, 2007, Vanda Pharmaceuticals Inc. issued a press release disclosing
certain Phase III efficacy data from its New Drug Application for iloperidone.
The full text of this press release is furnished as Exhibit 99.1 to this Current
Report on Form 8-K. Posters describing such data in greater detail will be
posted on Vanda’s website at http://www.vandapharma.com
on
December 13, 2007.
Item
9.01. Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No.
|
|
Description
|
|
99.1
|
|
Press
release of Vanda Pharmaceuticals Inc. dated December 12,
2007.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
VANDA
PHARMACEUTICALS INC.
|
||
|
|
|
|
|
|
By:
|
/s/
Steven A. Shallcross
|
|
|
|
Name:
Steven A. Shallcross
|
|
|
|
Title:
Senior Vice President, Chief Financial Officer and
Treasurer
|
Dated:
December 12, 2007